What is acute promyelocytic leukaemia?
Acute promyelocytic leukaemia (APL) is a fast-growing blood cancer. It is a distinct subtype of acute myeloid leukaemia (AML) in which immature white blood cells called promyelocytes build up in the bone marrow and blood.
APL is caused by one specific gene change, a fusion of the PML and RARA genes. This fusion blocks the cells from maturing. It also makes the leukaemia cells release substances that upset blood clotting, so APL often starts with serious bleeding.
APL is a medical emergency. Without fast treatment, many people die in the first days or weeks, mainly from bleeding in the brain or lungs.
The good news is that APL is now one of the most curable leukaemias. Two medicines that target the PML-RARA protein, all-trans retinoic acid (ATRA) and arsenic trioxide (ATO), cure around 9 in 10 people who get through the first weeks of treatment.
1. Key facts at a glance
| Feature | Details |
|---|---|
| Share of AML | About 5-15% of adult AML cases |
| Typical age | Mostly young and middle-aged adults; median age about 40-45. Less common in children and older people |
| Sex | Men and women are affected about equally |
| Populations | Reported more often in people of Latin American (Hispanic) origin |
| Cause | An acquired fusion of the PML gene (chromosome 15) and the RARA gene (chromosome 17), usually from the translocation t(15;17) |
| Main danger | A clotting disorder that causes bleeding and, less often, clots |
| Main treatment | ATRA plus arsenic trioxide, with chemotherapy added for high-risk disease |
| Outlook | Long-term survival about 90% or more in people who complete treatment |
2. Causes and risk factors
2.1 The PML-RARA fusion
In almost all cases of APL, parts of chromosome 15 and chromosome 17 swap places. This is called the translocation t(15;17)(q24;q21). It joins the PML gene to the RARA gene (retinoic acid receptor alpha).
Normally, RARA responds to vitamin A (retinoic acid) and helps white blood cells mature. The fused PML-RARA protein jams this process. The cells get stuck at the promyelocyte stage and keep dividing.
ATRA and arsenic trioxide both work by breaking down the PML-RARA protein. This lets the leukaemia cells mature and die. APL is one of the clearest examples in medicine of a cancer cured by drugs that hit its root cause.
2.2 Rare variant forms
In about 1-2% of cases, RARA is joined to a different partner gene. The 2022 WHO classification lists these separately as AML with other RARA rearrangements. This matters for treatment:
| Partner gene | Response to ATRA | Response to arsenic |
|---|---|---|
| NPM1-RARA, NUMA1-RARA | Usually sensitive | Variable |
| ZBTB16 (PLZF)-RARA | Resistant | Resistant |
| STAT5B-RARA | Resistant | Resistant |
People with resistant variants are treated with standard AML chemotherapy.
2.3 Risk factors
There is usually no clear cause, and APL is not inherited. Known or suspected risk factors include:
| Risk factor | Notes |
|---|---|
| Previous cancer treatment | Therapy-related APL can follow chemotherapy with topoisomerase II drugs (for example mitoxantrone or epirubicin) or radiotherapy, often for breast cancer or multiple sclerosis |
| Ethnic background | Higher rates in people of Latin American origin |
| Obesity | Linked to APL in some studies |
3. How does it look?
APL is diagnosed in the laboratory, but some features can be seen on the body and many are visible under the microscope.
3.1 Signs on the body
| Sign | What it looks like |
|---|---|
| Petechiae | Tiny red or purple pin-point spots on the skin, often on the legs or inside the mouth |
| Bruises (ecchymoses) | Large bruises after minor knocks, or with no injury at all |
| Bleeding gums and nosebleeds | Oozing that is hard to stop |
| Bleeding from needle sites | Blood seeping from drip or blood-test sites |
| Pale skin | Caused by anaemia |
| Eye changes | Bleeding in the white of the eye or the retina |
Unlike some other leukaemias, APL rarely causes large lymph nodes, a big spleen or swollen gums from leukaemia cells.
3.2 Under the microscope
| Feature | Description |
|---|---|
| Abnormal promyelocytes | Large cells packed with coarse pink-purple granules that may hide the nucleus |
| Nucleus | Often folded or two-lobed, sometimes called “butterfly” or “bilobed” |
| Auer rods | Needle-shaped crystals in the cytoplasm. They can be seen in other AMLs too, but in APL they are often numerous |
| Faggot cells | Cells that contain bundles of many Auer rods, like a bundle of sticks; very typical of APL |
| Microgranular (hypogranular) variant | About 15-20% of cases. Granules are too fine to see, nuclei are strongly two-lobed, and the white count is usually high |
3.3 Laboratory pattern
| Test | Typical result in APL |
|---|---|
| Full blood count | Low platelets and anaemia. White count is usually low in classic APL but high in the microgranular variant |
| Clotting tests | Low fibrinogen, high D-dimer and a prolonged prothrombin time: the picture of disseminated intravascular coagulation (DIC) with strong fibrinolysis |
| Flow cytometry | Cells positive for CD33 and CD13 (often CD117), and usually negative for HLA-DR and CD34; the microgranular variant may express CD2 and CD34 |
| Cytochemistry | Strongly positive for myeloperoxidase |
| Genetic tests | t(15;17) on karyotype; PML-RARA fusion by FISH and RT-PCR |
4. Symptoms
Symptoms of APL usually develop over days to a few weeks. They come from two problems: the leukaemia crowding out normal blood cells, and the clotting disorder.
4.1 Symptoms from low blood counts
| Symptom | Cause |
|---|---|
| Tiredness, weakness, breathlessness | Anaemia (low red cells) |
| Pale skin, dizziness, fast heartbeat | Anaemia |
| Fever and infections | Too few working white cells (neutrophils) |
| Easy bruising and red spots | Low platelets |
4.2 Symptoms from the clotting disorder
Bleeding is the most important symptom of APL. It is often worse than the platelet count alone would suggest.
| Type of bleeding or clotting | Examples |
|---|---|
| Skin and mucous membranes | Bruises, petechiae, bleeding gums, nosebleeds |
| Heavy periods | Very heavy or prolonged menstrual bleeding |
| Blood in urine, stools or vomit | Bleeding in the kidneys, bladder or gut |
| Bleeding in the brain | Sudden severe headache, confusion, weakness, fits or drowsiness; this is the leading cause of early death |
| Bleeding in the lungs | Coughing blood, breathlessness |
| Blood clots | Less common; deep vein thrombosis, lung clots or stroke |
4.3 When to get urgent help
Go to an emergency department straight away if you have:
- bleeding that will not stop, or many new bruises or red spots
- a sudden severe headache, confusion, vision changes, weakness or trouble speaking
- coughing or vomiting blood
- a high fever with low blood counts
If APL is suspected, doctors start ATRA immediately, even before genetic tests confirm the diagnosis.
5. Diagnosis
| Step | Purpose |
|---|---|
| Blood count and blood film | Shows low counts and abnormal promyelocytes |
| Clotting screen | Fibrinogen, D-dimer, prothrombin time and aPTT; repeated at least daily early on |
| Bone marrow sample | Confirms the leukaemia and gives cells for genetic tests. Often done from a blood sample alone if bleeding risk is high |
| PML-RARA by FISH or RT-PCR | Confirms the diagnosis, often within hours to a day; RT-PCR also identifies the transcript type for later monitoring |
| Karyotype | Detects t(15;17) and other chromosome changes |
| Kidney and liver tests, electrolytes | Baseline before treatment |
| ECG and heart scan | Checks the QT interval before arsenic, and heart function before anthracyclines |
| Pregnancy test | ATRA and arsenic can harm an unborn baby |
5.1 Risk groups
Doctors divide APL into risk groups using the white blood cell count (WBC) at diagnosis, based on the Sanz score:
| Risk group | White cell count | Usual approach |
|---|---|---|
| Low or intermediate (non-high) risk | 10 x 109/L or less | ATRA plus arsenic trioxide, without chemotherapy |
| High risk | Above 10 x 109/L | ATRA plus arsenic with an anthracycline (such as idarubicin) or gemtuzumab ozogamicin, or ATRA plus chemotherapy |
6. Treatment
6.1 Emergency care in the first days
The first priority is to stop bleeding and start ATRA at once. The European LeukemiaNet (ELN) recommends:
| Measure | Target or note |
|---|---|
| Start ATRA on suspicion | Do not wait for genetic confirmation |
| Platelet transfusions | Keep platelets above 30-50 x 109/L |
| Fibrinogen replacement | Cryoprecipitate or fibrinogen concentrate to keep fibrinogen above 1-1.5 g/L |
| Fresh frozen plasma | To correct a prolonged clotting time |
| Avoid invasive procedures | Central lines, lumbar punctures and other procedures are delayed if possible |
| Heparin and tranexamic acid | Not routinely recommended |
6.2 Standard-risk APL: ATRA plus arsenic
For non-high-risk APL, ATRA plus arsenic trioxide without chemotherapy is the standard of care. In the Italian-German APL0406 trial, it was better than ATRA plus chemotherapy:
| Result (about 4 years) | ATRA + arsenic | ATRA + chemotherapy |
|---|---|---|
| Event-free survival | 97% | 80% |
| Overall survival | 99% | 93% |
Treatment has two phases:
| Phase | What happens | Length |
|---|---|---|
| Induction | Daily ATRA tablets and arsenic infusions until complete remission | Usually 4-8 weeks, often in hospital |
| Consolidation | Courses of ATRA and arsenic to remove the remaining leukaemia | About 7 months in total |
Maintenance treatment is not needed after ATRA plus arsenic. In China, an oral arsenic preparation (realgar-indigo naturalis formula) was as effective as intravenous arsenic in a randomised trial, and allows much of treatment to be given at home.
6.3 High-risk APL
People with a high white cell count have more early bleeding and more relapses. Options include:
| Approach | Evidence |
|---|---|
| ATRA + arsenic + idarubicin or gemtuzumab ozogamicin | Used in the UK AML17 and Australasian APML4 trials. The APOLLO trial (2025) found ATRA plus arsenic with a short course of idarubicin better than ATRA plus chemotherapy |
| ATRA + anthracycline chemotherapy (AIDA-type) | The older standard, often followed by 2 years of maintenance |
| Hydroxyurea | To control a rising white count during ATRA plus arsenic |
6.4 Main side effects and complications
| Problem | What it is | How it is managed |
|---|---|---|
| Differentiation syndrome | Affects about 1 in 4 people. Maturing leukaemia cells release chemicals that cause fever, breathlessness, fluid on the lungs, weight gain, low blood pressure and kidney problems | Dexamethasone 10 mg twice daily at the first sign; ATRA or arsenic may be paused. Steroids are often given as prevention when the white count is high |
| QT prolongation (arsenic) | A change in heart rhythm that can rarely cause dangerous arrhythmias | Regular ECGs; keep potassium and magnesium normal; avoid other QT-prolonging drugs; pause if QTc is above 500 ms |
| High white count | Common on ATRA plus arsenic | Hydroxyurea |
| Liver changes | Raised liver enzymes | Dose pause or reduction |
| ATRA effects | Headache, dry skin and lips, raised blood fats, and raised pressure in the skull (pseudotumour cerebri), especially in children | Painkillers, moisturisers, dose reduction |
| Infections | More frequent with chemotherapy | Antibiotics and antifungals as needed |
6.5 Monitoring for remaining disease
Doctors check for PML-RARA with sensitive RT-PCR tests. The key goal is a negative test at the end of consolidation (molecular remission).
| Group | Usual monitoring after treatment |
|---|---|
| Standard risk, PCR negative after consolidation | Further routine testing may be limited, as relapse is rare |
| High risk | PCR every 3 months for about 2-3 years |
| PCR becomes positive again | Repeat test within 2-4 weeks; confirmed molecular relapse is treated straight away |
6.6 Relapsed APL
Relapse is uncommon after modern treatment (about 5% in standard risk). It is usually treated with arsenic-based therapy, often with ATRA. A second molecular remission is often followed by:
| Situation | Usual next step |
|---|---|
| PCR negative in second remission | Autologous stem cell transplant (using your own stem cells) |
| PCR still positive | Allogeneic stem cell transplant (from a donor) |
| Brain or spinal fluid involvement | Treatment into the spinal fluid; sometimes radiotherapy |
7. Special situations
| Situation | Key points |
|---|---|
| Children | Treated with similar ATRA and arsenic regimens, with lower ATRA doses to reduce headache and pseudotumour cerebri. Outcomes are excellent |
| Older adults | ATRA plus arsenic is usually well tolerated and avoids chemotherapy |
| Pregnancy | Arsenic is avoided throughout pregnancy. ATRA is avoided in the first trimester; in the second and third trimesters ATRA, often with an anthracycline, can be used. A specialist team plans care |
| Therapy-related APL | Responds to the same treatment as other APL, with similar results |
8. Outlook (prognosis)
| Measure | Approximate figure |
|---|---|
| Complete remission | 90-100% in clinical trials |
| Early death in trials | About 5% or less |
| Early death in everyday practice | Higher, about 10-20% in population studies, mostly from bleeding before or soon after diagnosis |
| Long-term survival (standard risk, ATRA + arsenic) | Over 90% |
| Long-term survival (high risk) | About 80-90% |
The biggest danger is in the first two weeks. Prompt recognition and starting ATRA early save lives. Once remission is reached, most people are cured and can return to normal life.
9. Living with and after APL
| Topic | Practical advice |
|---|---|
| During induction | Expect a hospital stay of several weeks with daily blood tests |
| Bleeding precautions | Use a soft toothbrush and electric razor; avoid aspirin and ibuprofen unless your team agrees |
| Infection precautions | Report a temperature of 38 C or more straight away |
| Contraception | Use reliable contraception during treatment and for the time your team advises afterwards |
| Vaccines | Inactivated vaccines are usually fine; avoid live vaccines during treatment unless your team says otherwise |
| Late effects | After anthracyclines, long-term heart checks may be advised; after ATRA plus arsenic alone, late effects are few |
10. Frequently asked questions
| Question | Answer |
|---|---|
| Is APL the same as AML? | APL is a subtype of AML, but it is treated very differently and has a much better outlook |
| Is arsenic a poison? | In high doses, yes. In carefully measured medical doses it is a highly effective targeted cancer drug |
| Is APL inherited? | No. The gene fusion is acquired in the blood cells and is not passed to children |
| Will I need a stem cell transplant? | Not usually. Transplants are mainly used after a relapse |
| Should I avoid vitamin A? | ATRA is a form of vitamin A. Avoid vitamin A supplements during treatment unless your doctor advises otherwise |
| Can I have children afterwards? | Many people do. ATRA plus arsenic is thought to have little effect on fertility, but discuss fertility before treatment if possible |
Resources
- Khoury, J.D. et al. (2022) ‘The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms’, Leukemia, 36(7), pp. 1703-1719.
- Arber, D.A. et al. (2022) ‘International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data’, Blood, 140(11), pp. 1200-1228.
- Sanz, M.A. et al. (2019) ‘Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet’, Blood, 133(15), pp. 1630-1643.
- de The, H., Pandolfi, P.P. and Chen, Z. (2017) ‘Acute promyelocytic leukemia: a paradigm for oncoprotein-targeted cure’, Cancer Cell, 32(5), pp. 552-560.
- Lo-Coco, F. et al. (2013) ‘Retinoic acid and arsenic trioxide for acute promyelocytic leukemia’, New England Journal of Medicine, 369(2), pp. 111-121.
- Platzbecker, U. et al. (2017) ‘Improved outcomes with retinoic acid and arsenic trioxide compared with retinoic acid and chemotherapy in non-high-risk acute promyelocytic leukemia: final results of the randomized Italian-German APL0406 trial’, Journal of Clinical Oncology, 35(6), pp. 605-612.
- Burnett, A.K. et al. (2015) ‘Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial’, The Lancet Oncology, 16(13), pp. 1295-1305.
- Iland, H.J. et al. (2015) ‘Use of arsenic trioxide in remission induction and consolidation therapy for acute promyelocytic leukaemia in the Australasian Leukaemia and Lymphoma Group (ALLG) APML4 study: a non-randomised phase 2 trial’, The Lancet Haematology, 2(9), pp. e357-e366.
- Platzbecker, U. et al. (2025) ‘Arsenic trioxide and all-trans retinoic acid combination therapy for the treatment of high-risk acute promyelocytic leukemia: results from the APOLLO trial’, Journal of Clinical Oncology, 43(29), pp. 3160-3169.
- Zhu, H.H. et al. (2018) ‘Oral arsenic plus retinoic acid versus intravenous arsenic plus retinoic acid for non-high-risk acute promyelocytic leukaemia: a non-inferiority, randomised phase 3 trial’, The Lancet Oncology, 19(7), pp. 871-879.
- Sanz, M.A. et al. (2000) ‘Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups’, Blood, 96(4), pp. 1247-1253.
- Park, J.H. et al. (2011) ‘Early death rate in acute promyelocytic leukemia remains high despite all-trans retinoic acid’, Blood, 118(5), pp. 1248-1254.
- Montesinos, P. et al. (2009) ‘Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy: characteristics, outcome, and prognostic factors’, Blood, 113(4), pp. 775-783.
- Lo-Coco, F., Hasan, S.K., Montesinos, P. and Sanz, M.A. (2013) ‘Biology and management of therapy-related acute promyelocytic leukemia’, Current Opinion in Oncology, 25(6), pp. 695-700.
- National Cancer Institute (2026) Acute Myeloid Leukemia Treatment (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/leukemia/hp/adult-aml-treatment-pdq (Accessed: October 2026).
Prepared by the editorial team, October 2026.